212 related articles for article (PubMed ID: 28239909)
21. Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant.
Shoreibah M; Orr J; Jones D; Zhang J; Venkata K; Massoud O
Hepatol Int; 2017 Sep; 11(5):434-439. PubMed ID: 28083718
[TBL] [Abstract][Full Text] [Related]
22. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
Wyles D; Pockros P; Morelli G; Younes Z; Svarovskaia E; Yang JC; Pang PS; Zhu Y; McHutchison JG; Flamm S; Lawitz E
Hepatology; 2015 Jun; 61(6):1793-7. PubMed ID: 25846014
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection.
Ojha RP; MacDonald BR; Chu TC; Fasanmi EO; Moore JD; Stewart RA
Antivir Ther; 2018; 23(7):585-592. PubMed ID: 29969099
[TBL] [Abstract][Full Text] [Related]
24. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.
Okubo T; Atsukawa M; Tsubota A; Toyoda H; Shimada N; Abe H; Kato K; Hayama K; Arai T; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kawamoto C; Iio E; Tanaka Y; Kumada T; Iwakiri K
Hepatol Int; 2018 Mar; 12(2):133-142. PubMed ID: 29600429
[TBL] [Abstract][Full Text] [Related]
26. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
[TBL] [Abstract][Full Text] [Related]
27. Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
Eisenberger U; Guberina H; Willuweit K; Bienholz A; Kribben A; Gerken G; Witzke O; Herzer K
Transplantation; 2017 May; 101(5):980-986. PubMed ID: 27495770
[TBL] [Abstract][Full Text] [Related]
28. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
Hepatology; 2016 Aug; 64(2):405-14. PubMed ID: 27115523
[TBL] [Abstract][Full Text] [Related]
29. The Effectiveness of Ledipasvir/Sofosbuvir in Youth With Genotype 4 Hepatitis C Virus: A Single Egyptian Center Study.
Fouad HM; Ahmed Mohamed A; Sabry M; Abdel Aziz H; Eysa B; Rabea M
Pediatr Infect Dis J; 2019 Jan; 38(1):22-25. PubMed ID: 30234791
[TBL] [Abstract][Full Text] [Related]
30. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
[TBL] [Abstract][Full Text] [Related]
31. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N
Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144
[TBL] [Abstract][Full Text] [Related]
32. Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study.
Soeiro CASP; Gonçalves CAM; Marques MSC; Méndez MJV; Tavares APRA; Horta AMLMFCA; Sarmento-Castro RMDR
BMC Infect Dis; 2018 Aug; 18(1):364. PubMed ID: 30075765
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach.
Johnson SW; Ammirati SR; Hartis CE; Weber SF; Morgan MR; Darnell TA; Silwal A; Schmidlin HN; Priest DH
Int J Antimicrob Agents; 2017 Jun; 49(6):778-781. PubMed ID: 28389353
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
[TBL] [Abstract][Full Text] [Related]
35. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
[TBL] [Abstract][Full Text] [Related]
36. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
[TBL] [Abstract][Full Text] [Related]
37. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
[TBL] [Abstract][Full Text] [Related]
39. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
El-Khayat HR; Kamal EM; El-Sayed MH; El-Shabrawi M; Ayoub H; RizK A; Maher M; El Sheemy RY; Fouad YM; Attia D
Aliment Pharmacol Ther; 2018 Mar; 47(6):838-844. PubMed ID: 29349793
[TBL] [Abstract][Full Text] [Related]
40. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]